Amid all the grim news about the pandemic, Americans finally have some cause for optimism. Over the past 10 days, Pfizer and Moderna have announced that analyses of the Phase III trials for their respective vaccine candidates show they are remarkably effective in preventing the infection. Pfizer announced last Monday that early analysis showed an efficacy rate of 90 percent for its vaccine, and the company has since announced the rate is closer to 95 percent.
What Makes the Pfizer and Moderna Vaccines So Promising
Using messenger RNA alleviates some of the problems with traditional vaccines.
